After-Hours Biotech Watch: IFRX, ABCL, RLYB Among Notable Risers

Several biotechnology and pharmaceutical stocks experienced notable after-hours gains on Friday, primarily fueled by positive financial results and upcoming clinical data. InflaRx N.V. (IFRX) led with a 63.41% surge ahead of its Phase 2a trial data and Q3 earnings release. Rallybio Corp. (RLYB) and Cellectis S.A. (CLLS) both saw double-digit percentage increases after reporting Q3 net income, reversing prior-year losses and showing revenue growth. BioRestorative Therapies Inc. (BRTX) also advanced following a Japanese patent allowance, while AbCellera Biologics Inc. (ABCL) partially recovered from an earlier decline despite a Q3 net loss.

Analysis

Biotechnology and pharmaceutical stocks experienced a strongly positive after-hours session, driven by upcoming clinical data and robust third-quarter earnings reports. InflaRx N.V. (IFRX) led this surge, climbing 63.41% to $2.01, ahead of its critical Phase 2a trial data release for INF904 and Q3 financial results scheduled for Monday morning. This indicates significant market anticipation around its clinical pipeline.

Several companies reported strong financial turnarounds. Rallybio Corp. (RLYB) posted a Q3 net income of $16.0 million, reversing an $11.5 million loss year-over-year, despite a slight revenue dip to $0.2 million. Similarly, Cellectis S.A. (CLLS) reported Q3 net income of $589 thousand, a substantial improvement from a $23.1 million loss, with revenues more than doubling to $37.2 million.

AbCellera Biologics Inc. (ABCL) partially recovered from an earlier 13.69% decline, advancing 6.51% after reporting a Q3 net loss of $57.1 million, though revenue increased to $9.0 million. BioRestorative Therapies Inc. (BRTX) gained 11.68% following a Japanese Patent Office Notice of Allowance for its ThermoStem platform, with Q3 results pending on November 12. These diverse catalysts underscore sector-specific drivers beyond just earnings.

Key Decisions for Investors

• Monitor InflaRx (IFRX) closely for Monday's Phase 2a data and Q3 results, as these events carry high potential for significant price volatility and long-term valuation shifts.
• Evaluate Rallybio (RLYB) and Cellectis (CLLS) for sustained profitability and revenue growth trajectory, given their strong Q3 reversals from prior-year losses.
• Assess the strategic implications of BioRestorative Therapies' (BRTX) Japanese patent allowance for its intellectual property strength and future commercial prospects.
• For AbCellera (ABCL), scrutinize the balance between increasing revenue and persistent net losses to determine operational efficiency and potential path to profitability.